Leica biosystems was advised that "tissue dried out on a run but wasn't discovered until 2 days after, the instrument has operated correctly since".On (b)(6) 2015, leica biosystems received information that re-biopsy of one (1) patient was necessary.The age and gender of the affected patient was provided.Investigation of this complaint by leica biosystems is in progress.
|
The initial 30-day fda 3500a report cited (b)(6) 2015 as the date of event (mm/dd/yyyy).Investigation of this complaint determined the actual date of event (mm/dd/yyyy) is (b)(6) 2015.Based on the information provided, it was determined that the sub-optimal tissue processing reported is derived from the "factory 8hr xylene standard" protocol started in retort a at 16:23pm on (b)(6) 2015, which completed at 06:58am on (b)(6) 2015; and the "factory 12hr xylene standard" protocol started in retort b at 17:13pm on (b)(6) 2015, which completed at 10:58am on (b)(6) 2015.No use error(s) was identified in the instrument log in relation to the interaction between the user and the instrument either prior to, or during execution of the "factory 8hr xylene standard" protocol started in retort a at 16:23pm on (b)(6) 2015 and the "factory 12hr xylene standard" protocol started in retort b at 17:13pm on (b)(6) 2015, from which sub-optimal tissue processing was reported.The root cause of the sub-optimal tissue processing reported could not be determined from the information available.
|